Cisapride in functional dyspepsia in general practice. A placebo-controlled, randomized, double-blind study

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue 1, 1997, Pages 193-199

  De Groot, G H ^a   De Both, P S M ^a  

^a RED CROSS HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISAPRIDE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPEPSIA; FEMALE; HELICOBACTER PYLORI; HISTOLOGY; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031022678     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1997.117288000.x     Document Type: Article

References (56)

1. Jones RH, Lydeard SE, Hobbs FDR, et al. Dyspepsia in England and Scotland. Gut 1990; 31: 401-5.
2. Johnsen R, Straume B, Førde OH. Peptic ulcer and non-ulcer dyspepsia - a disease and a disorder. Scand J Prim Health Care 1988; 6: 239-43.
3. Bernersen B, Johnsen R, Straume B, Burhol PG, Jenssen TG, Stakkevold PA. Towards a true prevalence of peptic ulcer: The Sorreisa gastrointestinal disorder study. Gut 1990; 31: 989-92.
4. Heyse PM, Rambaldo R, Hazelhoff B. Factors affecting short- and long-term outcome of a short therapeutic trial with cisapride in dyspeptic patients. Scand J Gastroenterol 1993; 28: 15-25.
5. Funch-Jensen P, Overview. Review in depth. Functional dyspepsia. Eur J Gastroenterol Hepatol 1992; 4: 595-6.
6. Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ, III. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992; 102: 1259-68.
7. Lydeard S, Jones R. Factors affecting the decision to consult with dyspepsia: comparison of consulters and non-consulters. J R Coll Gen Pract 1989; 39: 495-8.
8. Talley NJ, Colin-Jones DG, Koch KL, Koch M, Nyren O, Stanghellini V. Working Team Report. Functional dyspepsia: A classification with guidelines for diagnosis and management. Gastroenterol Int 1991; 4: 145-60.
9. Colin-Jones DG, Bloom B, Bodemar G, et al. Management of Dyspepsia: report of a working party. Lancet 1988, i: 576-9.
10. Barbara L, Camilleri M, Corinaldesi R. et al. Definition and investigation of dyspepsia: concensus of an international ad hoc working party. Dig Dis Sci 1989; 34: 1272-6.
11. Heading RC. Definitions of dyspepsia. Scand J Gastroenterol 1991; 26(Suppl. 182): 1-6.
12. Talley NJ. Symptom patterns in functional dyspepsia. Review in depth. Functional dyspepsia. Eur J Gastroenterol Hepatol 1992; 4: 597-601.
13. Mearin F, Malagelada JR. Upper gut motility and perception in functional dyspepsia. Review in depth. Functional dyspepsia. Eur J Gastroenterol Hepatol 1992; 4: 615-21.
14. Talley NJ, Phillips SF. Non-ulcer dyspepsia: potential causes and pathophysiology. Ann Int Med 1988; 108: 865-79.
15. Read NW, Khan MI. Gut sensitivity in functional dyspepsia. Review in depth. Functional dyspepsia. Eur J Gastroenterol Hepatol 1992; 4: 622-5.
16. Drossman DA. Psychosocial factors in functional dyspepsia. Review in depth. Functional dyspepsia. Eur J Gastroenterol Hepatol 1992; 4: 602-7.
17. Nyrén O. Functional dyspepsia: is gastric acid and/or Helicobacter pylori infection involved in the aetiology? Review in depth. Functional dyspepsia. Eur J Gastroenterol Hepatol 1992; 4: 608-14.
18. Waldron B, Cullen PT, Kumar R, et al. Evidence for hypomotility in non-ulcer dyspepsia: a prospective multifactorial study. Gut 1991; 32: 246-51.
19. Jian R, Ducrot F, Piedeloup C, Mary JY, Najean Y, Bernier J. Measurement of gastric emptying in dyspeptic patients: effect of a new gastrokinetic agent (cisapride). Gut 1985; 26: 352-8.
20. Jian R, Ducrot F, Ruskone A, et al .Symptomatic, radionuclide and therapeutic assessment of chronic idiopathic dyspepsia. A double-blind placebo-controlled evaluation of cisapride. Dig Dis Sci 1989; 34: 657-64.
21. Urbain JLC, Siegel JA, Debie NC, Pauwels SP. Effect of cisapride on gastric emptying in dyspeptic patients. Dig Dis Sci 1988; 33: 779-83.
22. Coutant G, François I, De Nutte N, De Cock G, Borgers P, Rutgeerts L. Dose-response study of cisapride in the management of 'non-ulcer dyspepsia'. Prog Med 1987; 43: 91-6.
23. Hausken T, Berstad A. cisapride treatment of patients with non-ulcer dyspepsia and erosive pyloric changes. A double-blind, placebo-controlled study. Scand J Gastroenterol 1992; 27: 213-7.
24. Milo R, Non-cholinergic, non-antidoperminergic treatment of chronic digestive symptoms suggestive of a motility disorder: a two-step pilot evaluation of cisapride. Curr Ther Res 1984; 36: 1053-62.
25. Deruyttere M, Lepoutre L, Heylen H, Samain H, Pennoit H. cisapride in the management of chronic functional dyspepsia: A multicentre, couble-blind, placebo-controlled study. Clin Ther 1987; 10: 44-51.
26. Deruyttere M, Milo R, Creytens G, Goethals C, Bourgeois E, Offner E. Therapy of chronic functional dyspepsia: multicentre cross-over study of cisapride and placebo. Prog Med 1987; 43(Suppl. 1): 61-8.
27. François I, De Nutte N. Non-ulcer dyspepsia: effect of the gastrointestinal prokinetic drug cisapride. Curr Ther Res 1987; 41: 891-8.
28. Goethals C, Van de Mierop L. cisapride in the treatment of chronic functional dyspepsia. Curr Ther Res 1987; 42: 261-7.
29. Hannon R. Efficacy of cisapride in patients with non-ulcer dyspepsia. A placebo-controlled study. Curr Ther Res 1987; 42: 814-22.
30. Rösch W. cisapride in non-ulcer dyspepsia. Results of a placebo-controlled trial. Scand J Gastroenterol 1987; 22: 161-4.
31. Van Ganse W, Reyntjes A. Clinical evaluation of cisapride in postprandial dyspepsia. Prog Med 1987; 43(Suppl. 1): 77-81.
32. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomack of patients with gastritis and peptic ulceration. Lancet 1984, i: 1311-5.
33. Jones DM, Lessels EM, Eldridge J. Campylobacter-like organisms on the gastric mucosa: culture, histological and serological studies. J Clin Pathol 1984; 37: 1002-6.
34. McNulty CAM, Watson DM. Spiral bacteria of the gastric antrum. Lancet 1984; i: 1068-9.
35. Rokkas T, Pursey C, Uzoechina E, et al. Non-ulcer dyspepsia and short-term de-nol therapy: a placebo-controlled trial with particular reference to the role of Campylobacter pylori. Gut 1988; 29: 1386-91.
36. Goh KL, Parasakthi N, Pen SC, Wong NW, Lo YL, Puthucheary SD. Helicobacter pylori infection and non-ulcer dyspepsia: the effect of treatment with colloidal bismuth subcitrate. Scand J Gastroenterol 1991; 26: 1123-31.
37. Borody T, Hennessy W, Daskalopoulos G, Carrick J, Hazell S. Double-blind trial of De-Nol in non-ulcer dyspepsia associated with Campylobacter pyloridis gastritis. Gastroenterology 1987; 92: 1324a( Abstract).
38. Lambert JR, Dunn K, Borromeo M, Korman MG, Hansky J. Campylobacter pylori - a role in non-ulcer dyspepsia? Scand J Gastroenterol 1989; 24(Suppl. 160): 7-13.
39. Kan JY, Tay HH, Wee A, Guan R, Math MV, Yap I. Effect of colloidal bismuth subcitrate on symptoms and gastric histology in non-ulcer dyspepsia. A double-blind, placebo-controlled study. Gut 1990; 31: 476-80.
40. Brassens-Rabbe MP, Megraud F, Denis R, et al. Seroepidemiology of Campylobacter pylori infection in four populations which differed in their ethnic and geographical characteristics. Proc Eur Meeting on Campylobacter pylori 1988.
41. Fiedorek SC, Evans DG, Evans DJ, et al. H. pylori infection epidemiology in children: importance of socioeconomic status, age, gender and race. Gastroenterology 1990; 98: A44( Abstract).
42. Graham DY, Klein PD, Opekun AR, et al. Epidemiology of Campylobacter pylori infection: ethnic considerations. Scand J Gastroenterol 1988; 23(Suppl. 142): 9-13.
43. Rokkas T, Pursey C, Uzoechina E, Dorrington L, Simmons LA, Fillipe MI. Campylobacter pylori and non-ulcer dyspepsia. Am J Gastroenterol 1987; 11: 1149-52.
44. Loffeld RJLF, Stobberingh E, Flendrig JA, Arends JW. Prexence of Helicobacter pylori in patients with non-ulcer dyspepsia revealing normal antral histological characteristics. Digestion 1990; 47: 29-34.
45. Gregson DB, Low DE, Cohen MM, et al. Prevalence of Campylobacter pylori gastritis among asymptomatic adults. Can Med Assoc J 1989; 140: 1449-53.
46. Deltrene M, Nyst JF, Jonas C, Glupczynski Y, Deprez C, Burette A. Clinical endoscopic and histological features in 1100 patients of whom 574 were colonized with Campylobacter pylori. Gastroenterol Clin Biol 1989; 13: 89B-95B(in French).
47. Bernersen B, Johnsen R, Bostad L, Straume B, Soomer AI, Burhol PG. Is Helicobacter pylori the cause of dyspepsia? Br Med J 1992; 304: 1276-9.
48. Chua A, Kennedy NP, Hamilton D, Keating JJ, Keeling PWN. Dysmotility-type-like organisms. Gut 1988; 29: 1437a(Abstract).
49. Vaira D, Holton J, Osborn J, et al. Endoscopy in dyspeptic patients: is gastric mucosal biopsy useful? Am J Gastroenterol 1990; 85: 701-4.
50. Mearin F, Morera M, Cucala M, et al. Symptoms in functional dyspepsia: relationship to gastro duodenal inflammation and dysmotility, duodenogastric reflux and Helicobacter pylori. Gastroenterology 1991, 100: A122(Abstract).
51. Testoni PA, Bagnolo F, Fanti L, Passaretti S, Tittobello A. Longterm oral cisapride improves interdigestive antroduodenal motility in dyspeptic patients. Gut 1990; 31: 286-90.
52. Corinaldesi R, Stanghellini V, Raiti C, Rea E, Salgemini R, Barbara L. Effect of chronic administration of cisapride on gastric emptying of a solid meal and on dyspeptic symptoms in patients with idiopathic gastroparesis. Gut 1990; 28: 300-5.
53. Börsch G, Schmidt M, Wegener M, et al. Campylobacter pylori: prospective analysis of clinical and histological factors associated with colonization of the upper gastrointestinal tract. Eur J Clin Invest 1988; 18: 133-8.
54. Sobala GM, Dixon MF, Axon ATR. Symptomatology of Helicobacter pylori associated dyspepsia. Eur J Gastroenterol Hepatol 1990; 2: 445-9.
55. Colling JS, Knill-Jones RP, Sloan JM, et al. A Comparison of symptoms between non-ulcer dyspepsia patients positive and negative for Helicobacter pylori. Ulster Med J 1991; 60: 21-7.
56. Loffeld RJLF, Potters HVPJ, Stobberingh E, Flendrig JA, Van Spreeuwel JD, Arends JW. Campylobacter associated gastritis in patients with non-ulcer dyspepsia - a double blind placebo controlled trial with colloid bismuth subcitrate. Gut 1989; 30; 1206-12.